Recent studies in our laboratory and others demonstrate that the CDK5 gene or its coactivators is amplified in a majority of human pancreatic cancers, expressed in all pancreatic cancer cell lines tested and that CDK5 activity increases as a consequence of the action of mutant k-Ras, which in turn enhaces pancreatic cancer cell growth, invasion and metastasis. We present evidence that the inhibition of CDK5 with a 3, 5- disubstituted pyrazole significantly reduces tumor size, metastasis, and vascularization of pancreatic tumors growing as xenografts in nude mice. We propose to study the effects of CDK5 inhibition on pancreatic adenocarcinoma progression in two distinct mouse models that recapitulate the human disease as it progresses from pancreatitis to PanIN lesions and from PanIN formation through metastasis. This study will focus on inhibiting CDK5 alone during early disease development and evaluate the therapeutic capacity of inhibiting CDK5 in later disease progression, using the inhibitor and Gemcitabine-Abraxane. A second benefit of inhibiting CDK5 is that it reduces pain, given its role in nociceptive signaling. Consequently, we will also undertake preclinical studies to determine if CDK5 inhibition blocks pain associated with pancreatitis and tumor growth. We will also undertake a Phase I human clinical trials that evaluate the clinical utility of inhibiting CDK5 in advanced pancreatic cancer patients that have failed other therapy options. In the longer term these studies may enable Phase II clinical trials for treateing pancreatitis and pancreatic cancer. We will also undertake parallel drug design studies to develop next-generation molecules that improve targeting of CDK5 in pancreatic cancer patients.
The research proposed in this project will explore the capacity of a new class of molecules that inhibit the activity of CDK5 in pancreatic cancer. These inhibitors have the potential to inhibit disease progression in premalignant and malignant lesions, and tumor associated pain. If successful these inhibitors will benefit every type of pancreatic cancer patient including those that have failed other therapies.
| Banerjee, Kasturi; Kumar, Sushil; Ross, Kathleen A et al. (2018) Emerging trends in the immunotherapy of pancreatic cancer. Cancer Lett 417:35-46 |
| Wiest, Edwin J; Smith, Heather Jensen; Hollingsworth, Michael A (2018) Met receptor inhibitor SU11274 localizes in the endoplasmic reticulum. Biochem Biophys Res Commun 501:858-862 |
| Chugh, Seema; Barkeer, Srikanth; Rachagani, Satyanarayana et al. (2018) Disruption of C1galt1 Gene Promotes Development and Metastasis of Pancreatic Adenocarcinomas in Mice. Gastroenterology 155:1608-1624 |
| Jahan, Rahat; Macha, Muzafar A; Rachagani, Satyanarayana et al. (2018) Axed MUC4 (MUC4/X) aggravates pancreatic malignant phenotype by activating integrin-?1/FAK/ERK pathway. Biochim Biophys Acta Mol Basis Dis 1864:2538-2549 |
| Qazi, Asif Khurshid; Siddiqui, Jawed A; Jahan, Rahat et al. (2018) Emerging therapeutic potential of graviola and its constituents in cancers. Carcinogenesis 39:522-533 |
| Tiriac, Hervé; Belleau, Pascal; Engle, Dannielle D et al. (2018) Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer. Cancer Discov 8:1112-1129 |
| Qi, Bowen; Crawford, Ayrianne J; Wojtynek, Nicholas E et al. (2018) Indocyanine green loaded hyaluronan-derived nanoparticles for fluorescence-enhanced surgical imaging of pancreatic cancer. Nanomedicine 14:769-780 |
| Goodwin, Justin; Choi, Hyunsung; Hsieh, Meng-Hsiung et al. (2018) Targeting Hypoxia-Inducible Factor-1?/Pyruvate Dehydrogenase Kinase 1 Axis by Dichloroacetate Suppresses Bleomycin-induced Pulmonary Fibrosis. Am J Respir Cell Mol Biol 58:216-231 |
| Coelho, Sílvia Castro; Reis, Daniel Pires; Pereira, Maria Carmo et al. (2018) Gold Nanoparticles for Targeting Varlitinib to Human Pancreatic Cancer Cells. Pharmaceutics 10: |
| Krishn, Shiv Ram; Ganguly, Koelina; Kaur, Sukhwinder et al. (2018) Ramifications of secreted mucin MUC5AC in malignant journey: a holistic view. Carcinogenesis 39:633-651 |
Showing the most recent 10 out of 191 publications
